Palmitoleic acid with infliximab for Crohn's healing
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether adding a natural fatty acid (palmitoleic acid) to the standard biologic drug infliximab can help heal the gut lining in people with moderate to severe Crohn's disease. If you have active Crohn's and haven't had intestinal surgery or used biologics recently, you may qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have Crohn's disease that was confirmed by imaging, biopsy, or endoscopy.
- Your Crohn's is currently active with a certain level of symptoms (CDAI 220–450).
- You have not taken any biologic drugs (like infliximab, adalimumab, or ustekinumab) in the past 8 weeks.
- You haven't taken fish oil or other omega-3 supplements in the past 8 weeks.
- You have not had any past intestinal surgery related to Crohn's.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
This study tests whether adding a special gut bacteria (Akkermansia muciniphila) to the standard biologic treatment infliximab can help heal the lining of the intestine better than infliximab alone. It is for people with active Crohn's disease who have not used biologics or antibiotics recently.
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.